Helus Pharma Names Dr. Ken Kramer as SVP Medical Affairs to Advance Phase 3 and Phase 2 Trials
Helus Pharma appointed Dr. Ken Kramer as Senior VP Medical Affairs, bringing 25 years of neuroscience experience and leadership of global neuropsychiatry teams at Bristol Myers Squibb and Karuna Therapeutics. He will shape medical strategy for the Phase 3 HLP003 adjunctive depression trial and the Phase 2 HLP004 anxiety study.
1. Appointment Details
Helus Pharma has appointed Dr. Ken Kramer as Senior Vice President, Medical Affairs effective April 16, 2026, elevating the company’s leadership with a seasoned medical affairs executive.
2. Professional Experience
Dr. Kramer brings over 25 years of neuroscience expertise, having led global medical neuroscience at Bristol Myers Squibb—including the launch of the first new schizophrenia treatment in over 70 years—expanded medical affairs at Karuna Therapeutics, and directed U.S. psychiatry teams at AbbVie.
3. Pipeline Impact
In his new role, Dr. Kramer will oversee medical strategy and key opinion leader engagement to support the Phase 3 HLP003 adjunctive major depressive disorder trial and the Phase 2 HLP004 generalized anxiety study.